Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) has earned a consensus recommendation of “Hold” from the fourteen analysts that are currently covering the company. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $72.25.

Several equities analysts have recently weighed in on the company. BMO Capital Markets reiterated a “hold” rating and set a $35.00 price objective on shares of Pacira Pharmaceuticals in a report on Thursday, November 3rd. Zacks Investment Research lowered Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 29th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $81.00 target price on shares of Pacira Pharmaceuticals in a research report on Wednesday, August 3rd. Mizuho reissued a “buy” rating and issued a $64.00 target price on shares of Pacira Pharmaceuticals in a research report on Tuesday, August 2nd. Finally, Brean Capital reissued a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Friday, August 5th.

Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) opened at 36.00 on Monday. Pacira Pharmaceuticals has a 52-week low of $30.25 and a 52-week high of $80.25. The company’s market capitalization is $1.35 billion. The stock has a 50 day moving average price of $34.38 and a 200 day moving average price of $39.39.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings data on Wednesday, November 2nd. The company reported $0.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.22. Pacira Pharmaceuticals had a negative return on equity of 1.52% and a negative net margin of 13.37%. The business had revenue of $68.40 million for the quarter, compared to analysts’ expectations of $67.16 million. During the same quarter in the previous year, the business posted $0.32 EPS. Pacira Pharmaceuticals’s revenue for the quarter was up 10.0% on a year-over-year basis. On average, analysts predict that Pacira Pharmaceuticals will post $0.55 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Fisher Asset Management LLC raised its position in Pacira Pharmaceuticals by 1.4% in the third quarter. Fisher Asset Management LLC now owns 6,282 shares of the company’s stock worth $215,000 after buying an additional 85 shares during the last quarter. Legacy Capital Partners Inc. increased its stake in Pacira Pharmaceuticals by 0.4% in the second quarter. Legacy Capital Partners Inc. now owns 23,200 shares of the company’s stock valued at $783,000 after buying an additional 100 shares during the period. Fox Run Management L.L.C. increased its stake in Pacira Pharmaceuticals by 0.8% in the third quarter. Fox Run Management L.L.C. now owns 13,400 shares of the company’s stock valued at $459,000 after buying an additional 100 shares during the period. Rothschild Asset Management Inc. increased its stake in Pacira Pharmaceuticals by 2.5% in the third quarter. Rothschild Asset Management Inc. now owns 7,137 shares of the company’s stock valued at $244,000 after buying an additional 175 shares during the period. Finally, American Century Companies Inc. increased its stake in Pacira Pharmaceuticals by 0.3% in the second quarter. American Century Companies Inc. now owns 66,391 shares of the company’s stock valued at $2,239,000 after buying an additional 206 shares during the period.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

5 Day Chart for NASDAQ:PCRX

Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.